Telix Pharmaceuticals (ASX:TLX) has announced a research collaboration with Osaka University.
Under the partnership, Telix will work with the University’s nuclear medicine department on the use of alpha nuclides for cancer therapy.
Telix is a clinical stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on molecularly charged radiation (MTR).
The company says there is considerable clinical and government interest in the use of alpha nuclide therapy in Japan, and, that the country is at the forefront of this research.
Shares in Telix (ASX:TLX) up 3.18 per cent to 65 cents yesterday